Opiant Pharmaceuticals, Inc. (OPNT)

NASDAQ: OPNT · IEX Real-Time Price · USD
15.63
0.93 (6.33%)
May 18, 2022 12:20 PM EDT - Market open
Market Cap79.51M
Revenue (ttm)45.87M
Net Income (ttm)-6.33M
Shares Out5.09M
EPS (ttm)0.51
PE Ratio30.65
Forward PE26.74
Dividendn/a
Ex-Dividend Daten/a
Volume35,073
Open14.90
Previous Close14.70
Day's Range14.48 - 15.69
52-Week Range7.34 - 37.71
Beta0.60
AnalystsBuy
Price Target41.82 (+167.6%)
Earnings DateMay 10, 2022

About OPNT

Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was incorpo...

IndustryPharmaceuticals
Founded2005
Employees37
Stock ExchangeNASDAQ
Ticker SymbolOPNT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for OPNT stock is "Buy." The 12-month stock price forecast is 41.82, which is an increase of 167.56% from the latest price.

Price Target
$41.82
(167.56% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Opiant Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update

SANTA MONICA, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdo...

1 week ago - GlobeNewsWire

Opiant Pharmaceuticals to Report First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 10,...

SANTA MONICA, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdo...

2 weeks ago - GlobeNewsWire

Opiant Pharmaceuticals Issues Statement in Response to Fake Press Release

SANTA MONICA, Calif. , April 29, 2022 /PRNewswire/ -- Opiant Pharmaceuticals (NASDAQ: OPNT) was the subject of a fake news release issued on Friday, April 29, 2022, that falsely stated Opiant announced ...

2 weeks ago - PRNewsWire

Why Opiant Pharmaceuticals Shares Are Soaring Today

Opiant Pharmaceuticals Inc (NASDAQ: OPNT) announced topline results from a pharmacodynamic (PD) study for OPNT003, nasal nalmefene for opioid overdose. This crossover study conducted in healthy voluntee...

2 weeks ago - Benzinga

Opiant Pharmaceuticals Announces Positive Topline Results from Head-to-Head Pharmacodynamic Study Comparing OPNT003, ...

SANTA MONICA, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced positive topline results from a pharmacodynamic (“PD”) study for OPNT003, ...

2 weeks ago - GlobeNewsWire

Opiant Pharmaceuticals Announces Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update

SANTA MONICA, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug over...

2 months ago - GlobeNewsWire

Opiant Pharmaceuticals to Participate in 32nd Oppenheimer Healthcare Conference

SANTA MONICA, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (Nasdaq: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose,...

2 months ago - GlobeNewsWire

Opiant Pharmaceuticals to Report Fourth Quarter 2021 Financial Results and Host Conference Call and Webcast on March ...

SANTA MONICA, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose,...

2 months ago - GlobeNewsWire

Opiant Pharmaceuticals Announces Positive Pharmacokinetic, Safety, and Tolerability Results From a Multi-Dose Study f...

SANTA MONICA, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced positive topline results from a multi-dose pharmacokinetic (“PK”) study for...

3 months ago - GlobeNewsWire

Under BARDA Contract, Opiant Pharma Secures Additional Funding Of $2M For Opioid Overdose Program

The Biomedical Advanced Research and Development Authority (BARDA) will provide additional funding of up to $2.2 million to support Opiant Pharmaceuticals Inc's (NASDAQ: OPNT) OPNT003, nasal nalmefene, ...

3 months ago - Benzinga

Opiant Pharmaceuticals Announces Additional $2.2 million Funding Under BARDA Contract for OPNT003 Nasal Nalmefene Dev...

SANTA MONICA, Calif., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced a modification to its contract with the Biomedical Advanced Research and De...

3 months ago - GlobeNewsWire

Opiant Pharma Starts Dosing In OPNT002 Mid-Stage Study For Alcohol Use Disorder

Opiant Pharmaceuticals Inc (NASDAQ: OPNT) has dosed the first patient in Phase 2 trial of OPNT002, nasal naltrexone, for Alcohol Use Disorder (AUD).  The trial will determine whether OPNT002 reduces hea...

3 months ago - Benzinga

Opiant Pharmaceuticals Announces First Patient Dosed in Phase 2 Trial of OPNT002, Nasal Naltrexone, for Alcohol Use D...

SANTA MONICA, Calif., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced that the first patient has been dosed in a Phase 2 clinical trial of OPNT00...

3 months ago - GlobeNewsWire

Correction: Opiant Pharmaceuticals Corrects Error in Issuing Duplicate Press Release Today

SANTA MONICA, Calif., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Correction: Opiant Pharmaceuticals, Inc. (“Opiant” or “Company”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat ...

3 months ago - GlobeNewsWire

Opiant Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SANTA MONICA, Calif., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant” or “Company”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions a...

3 months ago - GlobeNewsWire

Opiant Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Corporate Update

SANTA MONICA, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overd...

6 months ago - GlobeNewsWire

Opiant Pharmaceuticals to present at Jefferies Virtual London Healthcare Conference

SANTA MONICA, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (Nasdaq: OPNT), a company advancing medicines to better treat addictions and drug overdose, today announce...

6 months ago - GlobeNewsWire

Opiant Receives FDA Fast Track Designation for OPNT003, Nasal Nalmefene, for Treatment of Opioid Overdose

SANTA MONICA, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a company advancing medicines to better treat addictions and drug overdose, today announce...

6 months ago - GlobeNewsWire

Opiant Announces Publication of Manuscript Treatment of Overdose in the Synthetic Opioid Era in Peer-Reviewed Journal...

SANTA MONICA, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a company advancing medicines to better treat addictions and drug overdose, today announce...

6 months ago - GlobeNewsWire

Opiant Pharmaceuticals to Report Third Quarter 2021 Financial Results and Host Conference Call and Webcast on Novembe...

SANTA MONICA, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, ...

6 months ago - GlobeNewsWire

Opiant Pharmaceuticals to Participate in September Investor Conferences

SANTA MONICA, Calif., Aug. 25, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (Nasdaq: OPNT) today announced that members of the company's senior management team will participate in th...

8 months ago - GlobeNewsWire

Opiant Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Corporate Update

SANTA MONICA, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overd...

9 months ago - GlobeNewsWire

Opiant Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SANTA MONICA, Calif., July 20, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overd...

9 months ago - GlobeNewsWire

Opiant Pharmaceuticals Announces Appointment of Matthew Ruth as Chief Commercial Officer

SANTA MONICA, Calif., July 12, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overd...

10 months ago - GlobeNewsWire

Opiant Pharma Stock Surges On Positive Nasal Nalmefene Data In Opioid Overdose Study

Opiant Pharmaceuticals Inc (NASDAQ: OPNT) announced top-line results from its confirmatory pharmacokinetic study for OPNT003, nasal nalmefene, for opioid overdose.  The 68-subject study compared 3mg nal...

10 months ago - Benzinga